Related Experiment Video

Updated: Jul 15, 2026

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
09:12

Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods

Published on: May 11, 2018

A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression

Xiu-Fang Wang1, Marc Birringer, Lan-Feng Dong

  • 1Apoptosis Research Group and Genomics Research Centre, School of Medical Science, Griffith University, Southport, Queensland, Australia.

Cancer Research
|April 6, 2007
PubMed

Insights

Targeting erbB2-overexpressing cancer cells with alpha-tocopheryl succinate (alpha-TOS) conjugated to a peptide (alpha-TOS-LTVSPWY) induces apoptosis and suppresses tumors. This approach offers a novel strategy for treating erbB2-positive breast cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Overexpression of human epidermal growth factor receptor 2 (HER2, also known as erbB2) is linked to resistance to apoptosis in cancer cells.
  • Targeting specific molecular markers on cancer cells is a key strategy in developing more effective cancer therapies.

Purpose of the Study:

  • To investigate whether an erbB2-binding peptide (LTVSPWY) conjugated to alpha-tocopheryl succinate (alpha-TOS) can specifically target and induce apoptosis in erbB2-overexpressing cancer cells.
  • To evaluate the therapeutic efficacy of this targeted conjugate in preclinical models of breast cancer.

Main Methods:

  • Synthesis of alpha-tocopheryl succinate conjugated to an erbB2-binding peptide (alpha-TOS-LTVSPWY).
  • Treatment of erbB2-low and erbB2-high cancer cells with alpha-TOS and alpha-TOS-LTVSPWY, followed by apoptosis assessment.
  • Investigation of cellular uptake mechanisms and the role of endocytosis and lysosomal function.
  • Evaluation of tumor reduction in FVB/N c-neu transgenic mice bearing erbB2-high breast carcinomas.

Main Results:

  • Alpha-TOS-LTVSPWY induced significantly greater apoptosis in erbB2-high cells compared to erbB2-low cells or cells treated with unconjugated alpha-TOS.
  • Rapid accumulation of alpha-TOS-LTVSPWY was observed in erbB2-high cells.
  • Apoptosis induction by alpha-TOS-LTVSPWY was dependent on erbB2 expression and involved endocytotic and lysosomal pathways.
  • Treatment with alpha-TOS-LTVSPWY led to a reduction in erbB2-high breast tumors in a mouse model.

Conclusions:

  • A conjugate of alpha-tocopheryl succinate and an erbB2-binding peptide effectively targets erbB2-overexpressing cancer cells.
  • This targeted conjugate induces rapid apoptosis and demonstrates significant efficacy in suppressing erbB2-positive breast tumors.
  • The findings support the potential of this targeted therapy for treating HER2-positive breast cancers.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...